2 results match your criteria: "Department of Pharmaceutical Sciences University of Michigan Ann Arbor MI.[Affiliation]"
The COVID-19 pandemic continues to be a severe threat to human health, especially due to current and emerging SARS-CoV-2 variants with potential to escape humoral immunity developed after vaccination or infection. The development of broadly neutralizing antibodies that engage evolutionarily conserved epitopes on coronavirus spike proteins represents a promising strategy to improve therapy and prophylaxis against SARS-CoV-2 and variants thereof. Herein, a facile multivalent engineering approach is employed to achieve large synergistic improvements in the neutralizing activity of a SARS-CoV-2 cross-reactive nanobody (VHH-72) initially generated against SARS-CoV.
View Article and Find Full Text PDFArticle Synopsis
- There is a need to reduce the use of hypodermic injections for vaccines by exploring alternative delivery methods that enhance safety and coverage.
- The study focuses on developing controlled release microparticles made from poly (lactic--glycolic acid) (PLGA) that can encapsulate antigens and be incorporated into fast-dissolving microneedle patches for intradermal vaccination.
- These microneedles effectively penetrate the skin, delivering the microparticles that generate strong immune responses in animal models, offering a promising self-application method with logistical benefits over traditional injections.